Acute Myeloid Leukemia: The Good, the Bad, and the Ugly

Andrew Kuykendall, Nicolas Duployez, Nicolas Boissel, Jeffrey E. Lancet, John S. Welch

Research output: Contribution to journalReview article

13 Scopus citations


Acute myeloid leukemia (AML) was initially subdivided according to morphology (the French-American-British system), which proved helpful in pathologic categorization. Subsequently, clinical and genomic factors were found to correlate with response to chemotherapy and with overall survival. These included a history of antecedent hematologic disease, a history of chemotherapy or radiation therapy, the presence of various recurrent cytogenetic abnormalities, and, more recently, the presence of specific point mutations. This article reviews the biology and responses of one AML subgroup with consistent response and good outcomes following chemotherapy (core-binding factor leukemia), and two subgroups with persistently bad, and even ugly, outcomes (secondary AML and TP53-mutated AML).

Original languageEnglish
Pages (from-to)555-573
Number of pages19
JournalAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Issue number38
StatePublished - May 23 2018

Fingerprint Dive into the research topics of 'Acute Myeloid Leukemia: The Good, the Bad, and the Ugly'. Together they form a unique fingerprint.

  • Cite this